Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process

Journal of Pharmaceutical Sciences

Volumn 102, Issue 3, 2013, Pages 967-981

  Shah, Navnit ^a   Iyer, Raman M ^a   Mair, Hans Juergen ^b   Choi, Duk Soon ^a   Tian, Hung ^a   Diodone, Ralph ^b   Fähnrich, Karsten ^b   Pabst Ravot, Anni ^b   Tang, Kin ^a   Scheubel, Emmanuel ^b   Grippo, Joseph F ^a   Moreira, Sebastian A ^a   Go, Zenaida ^a   Mouskountakis, James ^a   Louie, Theresa ^a   Ibrahim, Prabha N ^c   Sandhu, Harpreet ^a   Rubia, Linda ^b   Chokshi, Hitesh ^a   Singhal, Dharmendra ^a   Malick, Waseem ^a   more..

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c PLEXXIKON INC   (United States)

Author keywords

Absorption; Amorphous; Bioavailability; Dissolution; Glass transition; Precipitation; Solid dispersion; solubility; Thermal analysis; X ray diffractometry

Indexed keywords

DRUG SOLVENT; EUDRAGIT; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; VEMURAFENIB;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CRYSTALLIZATION; DISPERSION; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DUST EXPOSURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH TEMPERATURE; HUMAN; HUMIDITY; HYDROGEN BOND; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MOISTURE; NORMAL HUMAN; OPEN STUDY; PARTICLE SIZE; PRECIPITATION; RANDOMIZED CONTROLLED TRIAL; SCANNING ELECTRON MICROSCOPY; THERMAL ANALYSIS; X RAY DIFFRACTION;

EID: 84878129271     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23425     Document Type: Article

References (59)

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2000. Guidance for Industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, August, pp 1-13.
3. Noyes A, Whitney W. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930-934.
4. Vemula VR, Lagishetty V, Lingala S. 2010. Solubility enhancement techniques. Int J Pharm Sci Rev Res 5(1):41-51.
5. Armstrong NA, James KC. 1980. Drug release from lipid-based dosage forms. Int J Pharm 6(3-4):195-204.
6. Narang AS, Delmarre D, Gao D. 2007. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 345(1-2):9-25.
7. Keck CM, Muller RH. 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62(1):3-16.
8. Rabinow BE. 2004. Nanosuspensions in drug delivery. Nat Rev Drug Discov 3(9):785-796.
9. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85(10):1017-1025.
10. Ntawukulilyayo JD, Bouckaert S, Remon JP. 1993. Enhancement of dissolution rate of nifedipine using sucrose ester coprecipitates. Int J Pharm 93:209-214.
11. Kai T, Akiyama Y, Nomura S, Sato M. 1996. Oral absorption improvement of poorly soluble drug using solid dispersion technique. Chem Pharm Bull 44:569-571.
12. Shin SC, Cho CW. 1997. Physicochemical characterizations of piroxicam-poloxamer solid dispersion. Pharm Dev Technol 2:403-407.
13. Okimoto K, Miyake M, Ibiki R, Yasumura M, Ohnishi N, Nakai T. 1997. Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropyl methylcellulose. Int J Pharm 159:85-93.
14. Kohri N, Yamayoshi Y, Xin H, Iseki K, Sato N, Todo S, Miyazaki K. 1999. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J Pharm Pharmacol 51:159-164.
15. Serajuddin, AT. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
16. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60.
17. Habib MJ, Venkataram S, Hussain MD. 2001. Fundamentals of solid dispersions. In Pharmaceutical solid dispersion technology; Habib MJ, Ed. 1st ed. Lancaster, Pennsylvania: Technomic Publishing Company, pp 20-28.
18. Bahl D, Bogner RH. 2006. Amorphization of indomethacin by co-grinding with neusilin US2: Amorphization kinetics, physical stability and mechanism. Pharm Res 23:2317-2325.
19. Bley H, Fussnegger B, Bodmeier R. 2010. Characterization and stability of solid dispersions based on PEG/polymer blends. Int J Pharm 390(2):165-173.
20. Kim EJ, Chun MK, Jang JS, Lee IH, Lee KR, Choi HK. 2006. Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur J Pharm Biopharm 64(2):200-205.
21. Moser JD, Broyles J, Liu L, Miller E, Wang M. 2008a. Enhancing bioavailability of poorly soluble drugs using spray dried solid dispersions. Am Pharm Rev Part I(9/10):68-71.
22. El-Badry E, Fathy M. 2006. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30. Drug Dev Ind Pharm 32(2):141-150.
23. Wu K, Li J, Wang W, Winstead DA. 2009. Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent. J Pharm Sci 98(7):2422-2431.
24. Evonik Industries. Accessed at: http://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-products/enteric-formulations/l-100-55/pages/default.aspx, Last accessed date Oct. 5, 2012.
25. Goskonda SR. 2009. Hypromellose phthalate. In Handbook of pharmaceutical excipients; Rowe RC, Sheskey PJ, Quinn ME, Eds. 6th ed. Grayslake, Illinois: RPS Publishing and APhA, pp 333-335.
26. Dressman JB, Kostewicz ES, Brauns U, Becker R. 2002. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res 19:345-349.
27. Marques M. 2004. Dissolution media simulating fasted and fed states. Dissolution Technol 11(2):16.
28. Connors RD, Elder EJ. 2004. Using a portfolio of particle growth technologies to enable delivery of drugs with poor water solubility. Drug Deliv Technol Deliv 4(8):78-83
29. Sharma S, Aggarwal G. 2010. Novel technologies for oral delivery of poorly soluble drugs. Res J Pharm Biol Chem Sci 1(4):292-305.
30. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS. 2008. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview. Mol Pharm 5(6):1003-1019.
31. Nagapudi K, Jona J. 2008. Amorphous active pharmaceutical ingredients in preclinical studies: Preparation, characterization, and formulation. Curr Bioactive Compounds 4:213-224.
32. Forster A, Hempenstall J, Tucker I, Rades T. 2001. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm 226:147-161.
33. Greenhalgh DJ, Williams AC, Timmins P, York P. 1999. Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci 88:1182-1190.
34. Hancock BC, Shamblin SL, Zografi G. 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperature. Pharm Res 12:799-806.
35. Al-Obaidi H, Buckton G. 2009. Evaluation of griseofulvin binary and ternary solid dispersions with HPMCAS. AAPS PharmSciTech 10(4):1172-1177.
36. Matsumoto T, Zografi G. 1999. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinylacetate) in relation to indomethacin crystallization. Pharm Res 16(11):1722-1728.
37. 4 J Colloid Sci 13:383-396.
38. Tanno F, Nishiyama Y, Kokubo H, Obara S. 2004. Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions. Drug Dev Ind Pharm 30(1):9-17.
39. Law D, Schmitt EA, Marsh KC, Everitt EA, Wang W, Fort JJ, Krill SL, Qiu Y. 2004. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluation. J Pharm Sci 93:563-570.
40. Six K, Verreck G, Peeters J, Brewster M, Van Den Mooter G. 2004. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci 93(1):124-131.
41. Sertsou G, Butler J, Scott A, Hempenstall J, Rades T. 2002. Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation. Int J Pharm 245(1-2):99-108.
42. Ghosh I, Snyder J, Vippagunta R, Alvine M, Vakil R, Tong WQ, Vippagunta S. 2011. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder. Int J Pharm 419:12-19.
43. Painter PC, Coleman MM. 1997. Crystallization, melting and glass transition. In Fundamentals of polymer science; Painter PC, Coleman MM, Eds. 2nd ed. Lancaster, Pennsylvania: Technomic Publishing Company, Inc., pp 259-303.
44. Vasanthavada M, Tong WQ, Joshi Y, Kislalioglu MS. 2005. Phase behavior of amorphous molecular dispersions. II. Role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm Res 22:440-448.
45. Gordon M, Taylor JS. 1952. Ideal copolymers and the second-order transitions of synthetic rubbers. 1: Non-crystalline copolymers. J Appl Chem 2:493-498.
46. Schneider HA 1997. Conformational entropy contributions to the glass temperature of blends of miscible polymers. J Res Natl Inst Stand Technol 102:229-248.
47. Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. 2005. Role of molecular interaction in stability of celecoxib-PVP amorphous systems. Mol Pharma 2(5):384-391.
48. Schreyer E, Palzer S. 2007. Caking of powder mixtures of crystalline and amorphous solids. Proceedings of PARTEC (Particle Technology) March 27-29, Nuremberg, Germany. pp 34-37.
49. Konno H, Handa T, Alonze DE, Taylor SL. 2008. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 70(2):493-499.
50. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS. 2008. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview. Mol Pharm 5(6):1003-1019.
51. Matteucci ME, Brettmann BK, Rogers TL, Elder EJ, III Williams RO, Johnston KP. 2007. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol Pharm 4(5):782-793.
52. Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GZ, Taylor LS. 2011. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci 100(8):3316-3331.
53. Yoshioka M, Hancock BC, Zografi G. 1994. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 83(12):1700-1705.
54. Rumondor CFA, Stanford LA, Taylor LS. 2009. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res 26(12):2599-2606.
55. Levine H, Slade L. 1988. Thermomechanical properties of small carbohydrate water glasses and rubbers. J Chem Soc Faraday Trans 1(84):2619-2633.
56. Ahlneck C, Zografi G. 1990. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int J Pharm 62:87-95.
57. Hancock BC, Zografi G 1994. The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res 11(4):471-477.
58. Elamin AA, Sebhatu T, Ahlneck C. 1995. The use of amorphous model substances to study mechanically activated materials in the solid state. Int J Pharm 119:25-36.
59. Makower B, Dye WB. 1956. Equilibrium moisture content and crystallisation of amorphous sucrose and glucose. J Agric Food Chem 4:72-77.